Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

Systemic mastocytosis either presents as aggressive neoplasm with short survival time or indolent systemic mastocytosis with normal life expectancy. In both instances, neoplastic mast cells usually harbor the D816V-mutated variant of KIT. Phenotypically, mast cells in systemic mastocytosis usually e...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2011-04, Vol.24 (4), p.585-595
Main Authors: Sotlar, Karl, Cerny-Reiterer, Sabine, Petat-Dutter, Karina, Hessel, Harald, Berezowska, Sabina, Müllauer, Leonhard, Valent, Peter, Horny, Hans-Peter
Format: Article
Language:English
Subjects:
631/67/1857
631/67/1990/283
Adult
Aged
Antigens
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Biopsy
Bone marrow
Bone Marrow - immunology
Bone Marrow - pathology
Bone Marrow Examination
DNA Mutational Analysis
Female
Humans
Immunohistochemistry
Ki-1 Antigen - analysis
Ki-1 Antigen - genetics
Laboratory Medicine
Leukemia
Life expectancy
Lymphoma
Male
Mast Cells - immunology
Mast Cells - pathology
Mastocytosis, Systemic - genetics
Mastocytosis, Systemic - immunology
Mastocytosis, Systemic - pathology
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Mutation
original-article
Pathology
Prognosis
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - analysis
Sarcoma
Tumors
Up-Regulation
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic mastocytosis either presents as aggressive neoplasm with short survival time or indolent systemic mastocytosis with normal life expectancy. In both instances, neoplastic mast cells usually harbor the D816V-mutated variant of KIT. Phenotypically, mast cells in systemic mastocytosis usually express CD25. However, no robust marker that discriminates between aggressive and indolent variants of systemic mastocytosis has been identified yet. We here report that CD30, also known as Ki-1 antigen, is expressed in neoplastic mast cells in a majority of patients with advanced systemic mastocytosis (11/13, 85%), whereas in most patients with indolent systemic mastocytosis (12/45, 27%; P
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.2010.224